.webp&w=828&q=75)
Felix Gold is advancing Alaskan antimony and gold assets, with potential US$18 million DOE pilot-processing funding driving investor interest. The non-dilutive funding could support domestic antimony supply, though project execution, permitting and financing risks remain.

Pro Medicus (ASX: PME) delivers record revenue growth, expanding margins, and accelerating AI‑driven innovation, reinforcing its global leadership in enterprise imaging and cloud‑based diagnostics.
.webp&w=828&q=75)
BlinkLab (ASX: BB1) is advancing its autism and ADHD assessment technology through clinical studies, FDA validation work, and research partnerships. Recent technical strength reflects growing investor interest, though regulatory and commercial risks remain.

Life360 delivers powerful subscription and advertising growth, expanding margins and accelerating global penetration. Strong MAU momentum, rising Paying Circles, and a breakout technical setup reinforce the company’s position as a high‑growth digital safety leader.
.webp&w=828&q=75)
Locksley Resources faces investor pressure after pausing Mojave exploration activities. The company is reassessing project spending, focusing on preserving assets, and reviewing future opportunities across its critical minerals portfolio.
.webp&w=828&q=75)
Austral Resources is drawing fresh attention through its Rocklands restart plans, Hammer Metals acquisition, copper exploration results, and infrastructure investment, while AR1’s chart approaches an important resistance zone with speculative risks still in focus.